Company / EPS (Diluted)
Viridian Therapeutics, Inc.\DE EPS (Diluted) History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.31
FY2023
5-year range
-$6.66 / -$4.05
FY2019-FY2023
Trend
-31.1%
vs FY2022
Sector context
#179 of 204
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's eps (diluted) of $-5.31 is lower than 88% of companies in the Health Care sector (FY2023). Improved from $-6.66 to $-5.31 over the past 2 years.
Based on SEC 10-K filings.
-5.31 in FY2023.
Improved from $-6.66 to $-5.31 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 204This company -$5.31 Sector average -$0.89
▼
-499.2% below sector average
Key checks
Key Insights
- In FY2023, eps (diluted) decreased 31.1% year-over-year.
- Ranks #179 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -$5.31 | -31.1% |
| FY2022 | -$4.05 | +39.2% |
| FY2021 | -$6.66 | +78.6% |
| FY2020 | -$31.13 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | -$28.21 | -34.2% |
| FY2016 | -$21.02 | -500.6% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026